These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 2074441

  • 1. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F, Escudier B.
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [Abstract] [Full Text] [Related]

  • 2. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 3. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T.
    J Biol Response Mod; 1990 Apr 01; 9(2):167-77. PubMed ID: 1971303
    [Abstract] [Full Text] [Related]

  • 4. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ, Gratama JW, van Putten WL, Stoter G, Bolhuis RL.
    Cancer Res; 1991 May 01; 51(9):2324-8. PubMed ID: 2015597
    [Abstract] [Full Text] [Related]

  • 5. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J.
    Nat Immun; 1992 May 01; 11(3):133-43. PubMed ID: 1392401
    [Abstract] [Full Text] [Related]

  • 6. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A.
    Cancer Res; 1989 Jan 01; 49(1):235-40. PubMed ID: 2783243
    [Abstract] [Full Text] [Related]

  • 7. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 8. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E.
    Hinyokika Kiyo; 1992 Nov 15; 38(11):1305-9. PubMed ID: 1485586
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D.
    Br J Cancer; 1999 Nov 01; 81(6):1009-16. PubMed ID: 10576658
    [Abstract] [Full Text] [Related]

  • 11. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
    Hayakawa M.
    Hinyokika Kiyo; 1992 Nov 01; 38(11):1311-8. PubMed ID: 1485587
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989 Nov 01; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 13. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW, Fuchs HA.
    J Rheumatol; 1994 Apr 01; 21(4):752-3. PubMed ID: 8035405
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1995 Aug 01; 16(2):283-8. PubMed ID: 7581149
    [Abstract] [Full Text] [Related]

  • 15. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ, Silver HK, Kong S.
    Cancer Res; 1990 Aug 15; 50(16):4906-10. PubMed ID: 2379154
    [Abstract] [Full Text] [Related]

  • 16. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 17. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ.
    Biol Blood Marrow Transplant; 1997 Apr 15; 3(1):34-44. PubMed ID: 9209739
    [Abstract] [Full Text] [Related]

  • 18. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A, Muul LM, Rosenberg SA.
    Cancer Res; 1988 Jan 01; 48(1):206-14. PubMed ID: 3257161
    [Abstract] [Full Text] [Related]

  • 19. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB.
    Cancer Res; 1988 Jun 15; 48(12):3461-9. PubMed ID: 3259468
    [Abstract] [Full Text] [Related]

  • 20. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Jun 15; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.